{
  "zip": "223 70",
  "sector": "",
  "fullTimeEmployees": 73,
  "longBusinessSummary": "BioInvent International AB (publ) focuses on the research and development of immunomodulating antibodies for the treatment of cancer in Sweden, Europe, the United States, and internationally. The company's lead drug candidate is BI-1206, a monoclonal antibody targeting CD32b, which is in Phase I/IIa clinical trials in patients with B-cell non-Hodgkin lymphoma and chronic lymphocytic leukaemia who are resistant to rituximab. It has a collaboration agreement with Oncurious to develop TB-403, which is in Phase I/II clinical trials used for the treatment of patients with medulloblastoma. The company is also developing immuno-modulatory antibodies, such as cancer-associated regulatory T cells for modulating the immune system and BI-1808, an antibody candidate. It has a strategic collaboration with Pfizer Inc. for the development of antibodies against tumour-associated myeloid cells; and partnership and collaboration with Transgene to co-develop multi-functional oncolytic viruses for treatment of solid tumors. The company also has an agreement with SkylineDx to characterize the gene expression and immunological signatures in tumors of patients pre-and post-treatment with BI-1206. The Company was founded in 1996 and is based in Lund, Sweden.",
  "city": "Lund",
  "phone": "46 4 62 86 85 50",
  "country": "Sweden",
  "companyOfficers": [],
  "website": "http://www.bioinvent.com",
  "maxAge": 1,
  "address1": "The Gamma Building",
  "industry": "",
  "address2": "Ideongatan 1",
  "previousClose": 5,
  "regularMarketOpen": 0.2,
  "twoHundredDayAverage": 0.95384306,
  "trailingAnnualDividendYield": null,
  "payoutRatio": null,
  "volume24Hr": null,
  "regularMarketDayHigh": 5,
  "navPrice": null,
  "averageDailyVolume10Day": 0,
  "totalAssets": null,
  "regularMarketPreviousClose": 5,
  "fiftyDayAverage": 3.4985468,
  "trailingAnnualDividendRate": null,
  "open": 0.2,
  "averageVolume10days": 0,
  "expireDate": null,
  "yield": null,
  "algorithm": null,
  "dividendRate": null,
  "exDividendDate": null,
  "beta": 0.93003,
  "circulatingSupply": null,
  "startDate": null,
  "regularMarketDayLow": 5,
  "priceHint": 4,
  "currency": "USD",
  "regularMarketVolume": 2500,
  "lastMarket": null,
  "maxSupply": null,
  "openInterest": null,
  "marketCap": 96940800,
  "volumeAllCurrencies": null,
  "strikePrice": null,
  "averageVolume": 120,
  "priceToSalesTrailing12Months": null,
  "dayLow": 5,
  "ask": 0,
  "ytdReturn": null,
  "askSize": 0,
  "volume": 2500,
  "fiftyTwoWeekHigh": 5,
  "forwardPE": null,
  "fromCurrency": null,
  "fiveYearAvgDividendYield": null,
  "fiftyTwoWeekLow": 0.14,
  "bid": 0,
  "tradeable": false,
  "dividendYield": null,
  "bidSize": 0,
  "dayHigh": 5,
  "exchange": "PNK",
  "shortName": "BIOINVENT AB",
  "longName": "BioInvent International AB (publ)",
  "exchangeTimezoneName": "America/New_York",
  "exchangeTimezoneShortName": "EST",
  "isEsgPopulated": false,
  "gmtOffSetMilliseconds": "-18000000",
  "underlyingSymbol": null,
  "quoteType": "EQUITY",
  "symbol": "BOVNF",
  "underlyingExchangeSymbol": null,
  "headSymbol": null,
  "messageBoardId": "finmb_139682",
  "uuid": "9df5ac7b-0362-3491-ae86-7ec9a5c811db",
  "market": "us_market",
  "annualHoldingsTurnover": null,
  "enterpriseToRevenue": null,
  "beta3Year": null,
  "profitMargins": -1.96976,
  "enterpriseToEbitda": null,
  "52WeekChange": null,
  "morningStarRiskRating": null,
  "forwardEps": null,
  "revenueQuarterlyGrowth": null,
  "sharesOutstanding": 350800000,
  "fundInceptionDate": null,
  "annualReportExpenseRatio": null,
  "bookValue": null,
  "sharesShort": null,
  "sharesPercentSharesOut": null,
  "fundFamily": null,
  "lastFiscalYearEnd": 1577750400,
  "heldPercentInstitutions": 0.28123,
  "netIncomeToCommon": null,
  "trailingEps": null,
  "lastDividendValue": null,
  "SandP52WeekChange": null,
  "priceToBook": null,
  "heldPercentInsiders": 0.23337999,
  "nextFiscalYearEnd": 1640908800,
  "mostRecentQuarter": 1601424000,
  "shortRatio": null,
  "sharesShortPreviousMonthDate": null,
  "floatShares": 20208714,
  "enterpriseValue": 7640057,
  "threeYearAverageReturn": null,
  "lastSplitDate": null,
  "lastSplitFactor": null,
  "legalType": null,
  "morningStarOverallRating": null,
  "earningsQuarterlyGrowth": null,
  "dateShortInterest": null,
  "pegRatio": null,
  "lastCapGain": null,
  "shortPercentOfFloat": null,
  "sharesShortPriorMonth": null,
  "category": null,
  "fiveYearAverageReturn": null,
  "regularMarketPrice": 0.2,
  "logo_url": "https://logo.clearbit.com/bioinvent.com"
}